300142 沃森生物
已收盘 07-09 15:00:00
资讯
新帖
简况
股市必读:沃森生物(300142)7月3日董秘有最新回复
证券之星 · 07-06
股市必读:沃森生物(300142)7月3日董秘有最新回复
股市必读:沃森生物(300142)6月30日董秘有最新回复
证券之星 · 07-01
股市必读:沃森生物(300142)6月30日董秘有最新回复
沃森生物:在研和处于临床研究阶段的mRNA疫苗产品包括新型冠状病毒变异株mRNA疫苗
证券之星 · 06-30
沃森生物:在研和处于临床研究阶段的mRNA疫苗产品包括新型冠状病毒变异株mRNA疫苗
6月29日沃森生物涨10.03%,疫苗ETF嘉实基金重仓该股
证券之星 · 06-29
6月29日沃森生物涨10.03%,疫苗ETF嘉实基金重仓该股
沃森生物:A群C群脑膜炎球菌多糖结合疫苗和ACYW135群脑膜炎球菌多糖疫苗国内市场价格整体保持稳定
证券之星 · 06-23
沃森生物:A群C群脑膜炎球菌多糖结合疫苗和ACYW135群脑膜炎球菌多糖疫苗国内市场价格整体保持稳定
沃森生物:目前公司持有亿腾嘉和医药集团有限公司的股权比例约为7.42%
证券之星 · 06-23
沃森生物:目前公司持有亿腾嘉和医药集团有限公司的股权比例约为7.42%
每周股票复盘:沃森生物(300142)13价肺炎疫苗印尼Ⅲ期临床达预期
证券之星 · 06-21
每周股票复盘:沃森生物(300142)13价肺炎疫苗印尼Ⅲ期临床达预期
沃森生物:爱森泽生物技术(昆明)有限公司属于公司合并财务报表范围内的子公司
证券之星 · 06-17
沃森生物:爱森泽生物技术(昆明)有限公司属于公司合并财务报表范围内的子公司
沃森生物:公司2026年度向特定对象发行A股股票的各项工作目前在按计划持续推进中
证券之星 · 06-17
沃森生物:公司2026年度向特定对象发行A股股票的各项工作目前在按计划持续推进中
沃森生物:公司四价流脑结合疫苗目前处于III期临床研究阶段
证券之星 · 06-17
沃森生物:公司四价流脑结合疫苗目前处于III期临床研究阶段
沃森生物(300142.SZ):13价肺炎球菌多糖结合疫苗印度尼西亚2p+1免疫程序Ⅲ期临床试验获得临床试验报告
智通财经 · 06-16
沃森生物(300142.SZ):13价肺炎球菌多糖结合疫苗印度尼西亚2p+1免疫程序Ⅲ期临床试验获得临床试验报告
沃森生物:山西制造基地规划主要是公司肠道微生态业务中核心菌群疗法的基石功能群营养产品
证券之星 · 06-12
沃森生物:山西制造基地规划主要是公司肠道微生态业务中核心菌群疗法的基石功能群营养产品
沃森生物:公司2026年度向特定对象发行A股股票的各项工作在按计划持续推进中
证券之星 · 06-10
沃森生物:公司2026年度向特定对象发行A股股票的各项工作在按计划持续推进中
沃森生物:优化核心自主产品产销,拓展海内外市场
证券之星 · 06-09
沃森生物:优化核心自主产品产销,拓展海内外市场
6月8日沃森生物跌5.07%,疫苗ETF嘉实基金重仓该股
证券之星 · 06-08
6月8日沃森生物跌5.07%,疫苗ETF嘉实基金重仓该股
沃森生物:公司持有上海柯君医药科技有限公司11.3852%股权
证券之星 · 06-01
沃森生物:公司持有上海柯君医药科技有限公司11.3852%股权
沃森生物:公司将在股东会审议通过后2个月内完成本次权益分派的实施
证券之星 · 06-01
沃森生物:公司将在股东会审议通过后2个月内完成本次权益分派的实施
沃森生物:公司将在股东会审议通过后2个月内完成本次权益分派的实施
证券之星 · 05-19
沃森生物:公司将在股东会审议通过后2个月内完成本次权益分派的实施
沃森生物:利用已上市或处于临床研究阶段的疫苗产品大力开发针对婴幼儿的联合疫苗
证券之星 · 05-11
沃森生物:利用已上市或处于临床研究阶段的疫苗产品大力开发针对婴幼儿的联合疫苗
股市必读:沃森生物(300142)5月8日披露最新机构调研信息
证券之星 · 05-11
股市必读:沃森生物(300142)5月8日披露最新机构调研信息
加载更多
公司概况
公司名称:
云南沃森生物技术股份有限公司
所属行业:
医药制造业
上市日期:
2010-11-12
主营业务:
云南沃森生物技术股份有限公司的主营业务是人用疫苗等生物技术药的研发、生产和销售。公司的主要产品是13价肺炎结合疫苗、双价HPV疫苗、23价肺炎多糖疫苗、b型流感嗜血杆菌结合疫苗、A群C群脑膜炎球菌多糖结合疫苗、ACYW135群脑膜炎球菌多糖疫苗、A群C群脑膜炎球菌多糖疫苗、吸附无细胞百白破联合疫苗。公司是中国首家、全球第二家自主研发并成功上市13价肺炎结合疫苗的企业,也是中国第二家、全球第四家自主研发并成功上市HPV疫苗的企业。
发行价格:
95.00
{"stockData":{"symbol":"300142","market":"SZ","secType":"STK","nameCN":"沃森生物","latestPrice":12.5,"timestamp":1783580610000,"preClose":12.31,"halted":0,"volume":52205208,"delay":0,"changeRate":0.0154,"floatShares":1577000000,"shares":1599000000,"eps":0.1787,"marketStatus":"已收盘","change":0.19,"latestTime":"07-09 15:00:00","open":12.18,"high":12.66,"low":11.99,"amount":646000000,"amplitude":0.0544,"askPrice":12.5,"askSize":1339,"bidPrice":12.49,"bidSize":1035,"shortable":0,"etf":0,"ttmEps":0.1787,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783647000000},"marketStatusCode":5,"adr":0,"adjPreClose":12.31,"symbolType":"stock","openAndCloseTimeList":[[1783560600000,1783567800000],[1783573200000,1783580400000]],"highLimit":13.54,"lowLimit":11.08,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1599348541,"isCdr":false,"pbRate":2.66,"roa":"--","peRate":69.949636,"roe":"1.41%","epsLYR":0.1111,"committee":0.112068,"marketValue":19992000000,"turnoverRate":0.0331,"status":0,"floatMarketCap":19712000000},"requestUrl":"/m/hq/s/300142","defaultTab":"news","newsList":[{"id":"2649348619","title":"股市必读:沃森生物(300142)7月3日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2649348619","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649348619?lang=zh_cn&edition=full","pubTime":"2026-07-06 03:32","pubTimestamp":1783279934,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘,沃森生物报收于13.2元,上涨1.62%,换手率4.28%,成交量67.52万手,成交额8.86亿元。董秘最新回复投资者: 公司定增方案是否已报国家有关单位审批?公司2026年度向特定对象发行A股股票的各项工作目前在按计划持续推进中,本次发行后续还需要经深圳证券交易所审核通过并经中国证监会同意注册等必需的行政审批后方可实施。当日关注点交易信息汇总:7月3日沃森生物主力资金净流入314.59万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070600001231.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0077","BK0070","300142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648656425","title":"股市必读:沃森生物(300142)6月30日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2648656425","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648656425?lang=zh_cn&edition=full","pubTime":"2026-07-01 01:32","pubTimestamp":1782840732,"startTime":"0","endTime":"0","summary":"截至2026年6月30日收盘,沃森生物报收于12.99元,上涨1.17%,换手率4.94%,成交量77.94万手,成交额10.0亿元。投资者: 广州实验室张琼团队联合复旦大学等单位于今年四月在《Cell Reports Medicine》发表研究,成功开发出一款针对首个牛传人H5N1高致病性禽流感病毒株的mRNA疫苗。这是迄今中国发表的最高水平的2.3.4.4b针对性mRNA疫苗研究。当日关注点交易信息汇总:6月30日沃森生物主力资金净流出2931.88万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100000848.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0046","BK0077","300142","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647535174","title":"沃森生物:在研和处于临床研究阶段的mRNA疫苗产品包括新型冠状病毒变异株mRNA疫苗","url":"https://stock-news.laohu8.com/highlight/detail?id=2647535174","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647535174?lang=zh_cn&edition=full","pubTime":"2026-06-30 16:18","pubTimestamp":1782807492,"startTime":"0","endTime":"0","summary":"目前,公司在研和处于临床研究阶段的mRNA疫苗产品包括新型冠状病毒变异株mRNA疫苗、新型冠状病毒变异株mRNA疫苗及其迭代疫苗新型冠状病毒变异株mRNA疫苗、呼吸道合胞病毒mRNA疫苗和冻干带状疱疹病毒mRNA疫苗,关于公司的研发布局和在研产品情况请以公司披露的公告为主。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000028938.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","300142","BK0070","BK0077","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647832267","title":"6月29日沃森生物涨10.03%,疫苗ETF嘉实基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647832267","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647832267?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:46","pubTimestamp":1782722813,"startTime":"0","endTime":"0","summary":"证券之星消息,6月29日沃森生物涨10.03%,收盘报12.84元,换手率6.7%,成交量105.69万手,成交额13.13亿元。融资融券方面近5日融资净流出330.01万,融资余额减少;融券净流出8900.0,融券余额减少。重仓沃森生物的前十大公募基金请见下表:根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共11家,其中持有数量最多的公募基金为嘉实基金的疫苗ETF嘉实。疫苗ETF嘉实目前规模为2.25亿元,最新净值0.5806,较上一交易日下跌4.27%,近一年上涨13.79%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900024713.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["562860","BK0077","BK0070","300142","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645788530","title":"沃森生物:A群C群脑膜炎球菌多糖结合疫苗和ACYW135群脑膜炎球菌多糖疫苗国内市场价格整体保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=2645788530","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645788530?lang=zh_cn&edition=full","pubTime":"2026-06-23 15:00","pubTimestamp":1782198044,"startTime":"0","endTime":"0","summary":"证券之星消息,沃森生物06月23日在投资者关系平台上答复投资者关心的问题。今年以来,公司A群C群脑膜炎球菌多糖结合疫苗和ACYW135群脑膜炎球菌多糖疫苗国内市场的价格整体上持续保持稳定。近期个别省份的中标价格调整仅为个例,调整后的价格将与国内市场的整体价格保持一致,具体情况请以相关省份的公示信息为准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300020079.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300142","159646","BK0077","BK0070","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645151002","title":"沃森生物:目前公司持有亿腾嘉和医药集团有限公司的股权比例约为7.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645151002","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645151002?lang=zh_cn&edition=full","pubTime":"2026-06-23 11:33","pubTimestamp":1782185624,"startTime":"0","endTime":"0","summary":"证券之星消息,沃森生物06月22日在投资者关系平台上答复投资者关心的问题。但之前这两个创新药的研发管线属于公司控股子公司嘉和生物,而据公司之前公告,沃森生物在2018年出售了嘉和生物的大部分股权。目前,公司持有亿腾嘉和医药集团有限公司的股权比例约为7.42%。关于公司在研产品和管线的信息请以公司在巨潮资讯网披露的相关公告和定期报告为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300016319.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300142","BK1583","BK1574","BK1161","BK0239","BK0046","06998","BK0070","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645696095","title":"每周股票复盘:沃森生物(300142)13价肺炎疫苗印尼Ⅲ期临床达预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2645696095","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645696095?lang=zh_cn&edition=full","pubTime":"2026-06-21 01:39","pubTimestamp":1781977149,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘,沃森生物报收于12.44元,较上周的11.56元上涨7.61%。本周,沃森生物6月18日盘中最高价报12.56元。本周关注点公司公告汇总:13价肺炎球菌多糖结合疫苗在印尼的Ⅲ期临床试验结果显示免疫原性和安全性达预设目标。公司公告汇总:沃森生物2025年度权益分派方案为每10股派1.25元现金(含税),股权登记日为2026年6月23日。本次权益分派实施后,公司2026年度向特定对象发行A股股票的发行价格将相应调整。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062100000295.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","BK0077","BK0046","BK0070","300142","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644746774","title":"沃森生物:爱森泽生物技术(昆明)有限公司属于公司合并财务报表范围内的子公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2644746774","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644746774?lang=zh_cn&edition=full","pubTime":"2026-06-17 20:52","pubTimestamp":1781700763,"startTime":"0","endTime":"0","summary":"3)是否已纳入公司合并报表并单独披露?爱森泽生物技术(昆明)有限公司作为公司光生物合成技术与产业化的平台,聚焦于医药健康天然产物的光生物合成,是公司在生物制造领域业务布局的重要组成部分,属于公司合并财务报表范围内的子公司。关于爱森泽生物技术(昆明)有限公司经营管理和业绩的相关信息请以公司披露的定期报告为准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700039477.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0239","BK0046","300142","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644379714","title":"沃森生物:公司2026年度向特定对象发行A股股票的各项工作目前在按计划持续推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2644379714","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644379714?lang=zh_cn&edition=full","pubTime":"2026-06-17 11:36","pubTimestamp":1781667369,"startTime":"0","endTime":"0","summary":"证券之星消息,沃森生物(300142)06月16日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘,你公司的定增工作是不是终止了,为什么不公告!沃森生物回复:尊敬的投资者,您好!公司2026年度向特定对象发行A股股票的各项工作目前在按计划持续推进中,本次发行后续还需要经深圳证券交易所审核通过并经中国证监会同意注册等必需的行政审批后方可实施,后续进展情况还请持续关注公司披露的信息。谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700016948.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0070","159982","BK0239","300142","BK0077","399300"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644797986","title":"沃森生物:公司四价流脑结合疫苗目前处于III期临床研究阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2644797986","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644797986?lang=zh_cn&edition=full","pubTime":"2026-06-17 11:33","pubTimestamp":1781667231,"startTime":"0","endTime":"0","summary":"证券之星消息,沃森生物06月16日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘您好,关于四价流脑结合疫苗:1)Ⅲ 期临床总结报告是否已正式定稿并提交 CDE?四价流脑结合疫苗迟迟没有批准的原因是否是数据很差沃森生物回复:尊敬的投资者,您好!公司四价流脑结合疫苗目前处于III期临床研究阶段,公司将按照国家对于注册临床试验的有关程序和要求推进相关工作。关于产品的后续进展情况请持续关注公司披露的信息。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700016768.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","BK0239","BK0046","300142","BK0077","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643737357","title":"沃森生物(300142.SZ):13价肺炎球菌多糖结合疫苗印度尼西亚2p+1免疫程序Ⅲ期临床试验获得临床试验报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2643737357","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643737357?lang=zh_cn&edition=full","pubTime":"2026-06-16 16:26","pubTimestamp":1781598369,"startTime":"0","endTime":"0","summary":"智通财经APP讯,沃森生物 发布公告,公司子公司玉溪沃森生物技术有限公司于近日收到13价肺炎球菌多糖结合疫苗在印度尼西亚开展的“2p+1”免疫程序Ⅲ期临床试验报告。玉溪沃森于2023 年9月收到印度尼西亚食品药品监督管理局签发的本疫苗的Ⅲ 期临床试验批件。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454914.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300142","BK0077","BK0239","BK0046","BK0070","159646"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642258077","title":"沃森生物:山西制造基地规划主要是公司肠道微生态业务中核心菌群疗法的基石功能群营养产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2642258077","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642258077?lang=zh_cn&edition=full","pubTime":"2026-06-12 08:46","pubTimestamp":1781225169,"startTime":"0","endTime":"0","summary":"证券之星消息,沃森生物06月11日在投资者关系平台上答复投资者关心的问题。山西拜诺作为公司微生态与特医产业化核心基地,请问:1)山西拜诺在微生态活菌制剂与特医产品中的战略定位,与无锡曼诺三合如何协同?2)洪洞基地产能规划、技术路线及核心产品管线?山西制造基地的规划主要是公司肠道微生态业务中核心菌群疗法的基石功能群营养产品。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061200005812.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300142","BK0077","BK0239","BK0046","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642105446","title":"沃森生物:公司2026年度向特定对象发行A股股票的各项工作在按计划持续推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2642105446","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642105446?lang=zh_cn&edition=full","pubTime":"2026-06-10 16:03","pubTimestamp":1781078596,"startTime":"0","endTime":"0","summary":"证券之星消息,沃森生物(300142)06月10日在投资者关系平台上答复投资者关心的问题。投资者提问:公司 20 亿定增自 4 月 3 日股东会通过后至今未提交深交所,请问材料准备是否遇阻?预计受理时间?请详细说明原因。沃森生物回复:尊敬的投资者,您好!公司2026年度向特定对象发行A股股票的各项工作在按计划持续推进中,本次发行后续还需要经深圳证券交易所审核通过并经中国证监会同意注册等必需的行政审批后方可实施,后续进展情况还请持续关注公司披露的信息。谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061000026230.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","300142","BK0239","BK0046","399300","BK0070","159982"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642146040","title":"沃森生物:优化核心自主产品产销,拓展海内外市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2642146040","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642146040?lang=zh_cn&edition=full","pubTime":"2026-06-09 20:51","pubTimestamp":1781009484,"startTime":"0","endTime":"0","summary":"证券之星消息,沃森生物06月08日在投资者关系平台上答复投资者关心的问题。公司将不断优化核心自主产品的生产和销售工作,坚持产品质量不松懈,深耕国内市场,拓展国际市场。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060900036551.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300142","BK0077","BK0070","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641107795","title":"6月8日沃森生物跌5.07%,疫苗ETF嘉实基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2641107795","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641107795?lang=zh_cn&edition=full","pubTime":"2026-06-08 16:57","pubTimestamp":1780909054,"startTime":"0","endTime":"0","summary":"证券之星消息,6月8日沃森生物跌5.07%创60日新低,收盘报11.23元,换手率3.72%,成交量58.72万手,成交额6.7亿元。重仓沃森生物的前十大公募基金请见下表:根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共11家,其中持有数量最多的公募基金为嘉实基金的疫苗ETF嘉实。疫苗ETF嘉实的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060800022543.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0046","BK0070","300142","562860","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640693190","title":"沃森生物:公司持有上海柯君医药科技有限公司11.3852%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2640693190","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640693190?lang=zh_cn&edition=full","pubTime":"2026-06-01 15:48","pubTimestamp":1780300087,"startTime":"0","endTime":"0","summary":"证券之星消息,沃森生物(300142)06月01日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘,贵司投资柯君医药为什么不公告?本次牵头柯君医药融资,贵司持股占比多少?沃森生物回复:尊敬的投资者,您好!根据《深圳证券交易所创业板股票上市规则》《公司章程》及公司《对外投资决策程序与规则》的相关规定,本次投资事宜经公司总裁办公会审议通过后实施。根据工商登记信息显示,本次投资于2026年4月完成了工商变更登记,公司持有上海柯君医药科技有限公司11.3852%股权,上海柯君医药科技有限公司现为公司的参股公司。谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100018683.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300142","BK0046","BK0070","BK0239","BK1161","BK1574","BK0077","159938","09939","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640939782","title":"沃森生物:公司将在股东会审议通过后2个月内完成本次权益分派的实施","url":"https://stock-news.laohu8.com/highlight/detail?id=2640939782","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640939782?lang=zh_cn&edition=full","pubTime":"2026-06-01 15:33","pubTimestamp":1780299215,"startTime":"0","endTime":"0","summary":"证券之星消息,沃森生物(300142)06月01日在投资者关系平台上答复投资者关心的问题。投资者提问:沃森生物近期股价一直低迷,公司的分红也一直推不出来,目前具体的分红时间定下来了嘛?公司的肠道益生菌减肥产品啥时候上市沃森生物回复:尊敬的投资者,您好!公司已于2026年4月29日召开2025年年度股东会,审议通过2025年年度权益分派事项,公司将在股东会审议通过后2个月内完成本次权益分派的实施,具体实施时间请关注公司后续披露的公告。谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100017161.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0070","300142","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636348888","title":"沃森生物:公司将在股东会审议通过后2个月内完成本次权益分派的实施","url":"https://stock-news.laohu8.com/highlight/detail?id=2636348888","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636348888?lang=zh_cn&edition=full","pubTime":"2026-05-19 08:42","pubTimestamp":1779151336,"startTime":"0","endTime":"0","summary":"证券之星消息,沃森生物(300142)05月18日在投资者关系平台上答复投资者关心的问题。投资者提问:请问贵公司何时分红沃森生物回复:尊敬的投资者,您好!公司已于2026年4月29日召开2025年年度股东会,审议通过2025年年度权益分派事项,公司将在股东会审议通过后2个月内完成本次权益分派的实施,具体实施时间请关注公司后续披露的公告。谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900009174.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0070","BK0239","BK0046","300142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634703409","title":"沃森生物:利用已上市或处于临床研究阶段的疫苗产品大力开发针对婴幼儿的联合疫苗","url":"https://stock-news.laohu8.com/highlight/detail?id=2634703409","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634703409?lang=zh_cn&edition=full","pubTime":"2026-05-11 16:42","pubTimestamp":1778488933,"startTime":"0","endTime":"0","summary":"证券之星消息,沃森生物05月11日在投资者关系平台上答复投资者关心的问题。在疫苗产品研发上,公司一方面将持续加强目前已上市品种的产品升级,开发更高价次肺炎球菌多糖结合疫苗、更高价次脑膜炎球菌疫苗、更高价次HPV疫苗,并进一步扩大适用人群范围;另一方面将不断加快创新性疫苗的研发布局,同时,利用已上市或处于临床研究阶段的疫苗产品大力开发针对婴幼儿的联合疫苗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100022348.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0070","300142","BK0077","159646"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634425515","title":"股市必读:沃森生物(300142)5月8日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2634425515","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634425515?lang=zh_cn&edition=full","pubTime":"2026-05-11 01:48","pubTimestamp":1778435296,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘,沃森生物报收于13.35元,上涨1.52%,换手率4.95%,成交量78.07万手,成交额10.45亿元。当日关注点来自交易信息汇总:5月8日主力资金净流入1834.41万元,游资资金同步净流入,散户资金呈净流出态势。来自机构调研要点:5月8日公司召开电话会议,副总裁、董事会秘书等高管参与交流。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100000869.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0046","BK0077","300142","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1783609140025,"stockEarnings":[{"period":"1week","weight":-0.0779},{"period":"1month","weight":0.1072},{"period":"3month","weight":-0.0116},{"period":"6month","weight":0.0259},{"period":"1year","weight":0.1211},{"period":"ytd","weight":0.1427}],"compareEarnings":[{"period":"1week","weight":-0.0344},{"period":"1month","weight":0.0029},{"period":"3month","weight":0.0012},{"period":"6month","weight":-0.0363},{"period":"1year","weight":0.1354},{"period":"ytd","weight":0.0005}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"云南沃森生物技术股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"118448人(较上一季度减少0.27%)","perCapita":"13313股","listingDate":"2010-11-12","address":"云南省昆明市五华区高新区科新路395号","registeredCapital":"159934万元","survey":" 云南沃森生物技术股份有限公司的主营业务是人用疫苗等生物技术药的研发、生产和销售。公司的主要产品是13价肺炎结合疫苗、双价HPV疫苗、23价肺炎多糖疫苗、b型流感嗜血杆菌结合疫苗、A群C群脑膜炎球菌多糖结合疫苗、ACYW135群脑膜炎球菌多糖疫苗、A群C群脑膜炎球菌多糖疫苗、吸附无细胞百白破联合疫苗。公司是中国首家、全球第二家自主研发并成功上市13价肺炎结合疫苗的企业,也是中国第二家、全球第四家自主研发并成功上市HPV疫苗的企业。","listedPrice":95},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"沃森生物(300142)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供沃森生物(300142)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"沃森生物,300142,沃森生物股票,沃森生物股票老虎,沃森生物股票老虎国际,沃森生物行情,沃森生物股票行情,沃森生物股价,沃森生物股市,沃森生物股票价格,沃森生物股票交易,沃森生物股票购买,沃森生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"沃森生物(300142)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供沃森生物(300142)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}